Predict your next investment

Corporation
HEALTHCARE | Biotechnology
sinovac.com

See what CB Insights has to offer

Founded Year

2009

Stage

Corporate Minority - P2P | IPO

Market Cap

0.46B

Stock Price

6.47

About Sinovac Biotech

Sinovac Biotech (NASDAQ: SVA) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies.

Sinovac Biotech Headquarter Location

No. 39 Shangdi Xi Road

Beijing, Beijing, 100085,

China

+86 10 8289 0088

Latest Sinovac Biotech News

Singapore breaks down COVID-19 deaths by vaccine, with Moderna seeing lowest rate

Jan 11, 2022

Sorry, but your browser needs Javascript to use this site. If you're not sure how to activate it, please refer to this site: https://www.enable-javascript.com/ People walk in and out of the Mass Rapid Transit subway station in Singapore's Chinatown district on Monday. | AFP-JIJI Jan 11, 2022 Singapore saw the fewest deaths among those administered a Moderna Inc. shot and the most among those who received Sinovac Biotech Ltd.’s vaccine, with the city-state’s highly inoculated population providing a glimpse into how different immunizations are holding up in the real world. Of the 802 people who died from COVID-19 last year in the city-state, 555, or about 70%, weren’t fully vaccinated, health minister Ong Ye Kung told parliament Monday, showing the life-saving impact of inoculation. Singapore found 11 deaths per 100,000 among people who received Sinovac shots and 7.8 deaths among those with Sinopharm. This number fell to 6.2 deaths for those with the messenger RNA (mRNA) shot jointly developed by Pfizer Inc. and BioNTech SE, and 1 fatality in those who were administered the vaccine from Moderna. While Ong added some caveats to his comments — the sample size was small and did not account for factors such as age and timing of vaccine doses — the findings will likely add to concerns around the efficacy of Sinovac’s and Sinopharm Group’s inactivated virus shots, which have been widely used in the developing world. Initial laboratory studies have already suggested that Sinovac, even with a booster dose, is not effective against the highly transmissible omicron variant that’s now dominating the world. The new and highly mutated variant is not yet circulating widely in the city-state, which has recorded more than 285,000 coronavirus infections throughout the pandemic and largely relied on the mRNA vaccines made by Moderna and Pfizer-BioNTech to grapple with a virus surge caused by the delta variant last year. About 87% of the total population was fully vaccinated as of Jan. 8, according to Ministry of Health data. Ong reiterated that the key strategy remains to live with COVID-19, which includes not locking down the country’s borders. The government “cannot overliberalize all social activities” and remove all restrictions. Singapore will respond “flexibly and appropriately to twists and turns that the pandemic situation may take,” he said. In a time of both misinformation and too much information, quality journalism is more crucial than ever. By subscribing, you can help us get the story right.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Sinovac Biotech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sinovac Biotech Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.